{"version":"1.0","type":"rich","provider_name":"\u003Cspan class=\"caps\"\u003EAIM\u003C\/span\u003E-\u003Cspan class=\"caps\"\u003EIMA\u003C\/span\u003E","provider_url":"https:\/\/aim-ima.be","title":"Prestation de services \u00e0 l\u2019industrie pharmaceutique \u00e0 la demande du gouvernement\u00a0:  Proc\u00e9dure \u003Cspan class=\"caps\"\u003EAIM\u003C\/span\u003E art. 111\/112\/113 demandes r\u00e9guli\u00e8res et de r\u00e9vision","author_name":"","width":"480","height":"295","url":"https:\/\/ima-aim.be\/Prestation-de-services-a-l","html":"\u003Ch4 class='title'\u003E\u003Ca href='https:\/\/ima-aim.be\/Prestation-de-services-a-l'\u003EPrestation de services \u00e0 l\u2019industrie pharmaceutique \u00e0 la demande du gouvernement\u00a0:  Proc\u00e9dure \u003Cspan class=\"caps\"\u003EAIM\u003C\/span\u003E art. 111\/112\/113 demandes r\u00e9guli\u00e8res et de r\u00e9vision\u003C\/a\u003E\u003C\/h4\u003E\u003Cblockquote class='spip'\u003EAfin de garder sous contr\u00f4le les d\u00e9penses relatives aux m\u00e9dicaments innovants, un m\u00e9canisme a \u00e9t\u00e9 mis en place pr\u00e9voyant la conclusion d\u2019un contrat entre les entreprises pharmaceutiques et l\u2019Institut national d\u2019assurance maladie-invalidit\u00e9 (\u003Cspan class=\"caps\"\u003EINAMI\u003C\/span\u003E) (art. 112 de l\u2019\u003Cspan class=\"caps\"\u003EA.R.\u003C\/span\u003E du 01.02.2018).\u003C\/blockquote\u003E\n"}